Risk factors for the onset of cervical intraepithelial neoplasia

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Persistent human papillomavirus (HPV) infection is a well-established cause of cervical intraepithelial neoplasia (CIN). Epidemiological studies show that while HPV infection is common, it is far more prevalent than CIN itself. Consequently, HPV testing exhibits moderate specificity and positive predictive value for detecting high-grade CIN. Currently, there is no optimal strategy for identifying HPV-positive women at high risk of CIN.

AIM: This study aims to assess the socioeconomic, behavioral, and comorbidity factors associated with an increased risk of developing cervical intraepithelial neoplasia.

MATERIAL AND METHODS: The study included 121 women who presented to the Medical Research and Education Center of Moscow State University in the period from 2022 to 2023. Pap-smear revealed normal data in 66 women (Group 1, NILM), mild cervical intraepithelial neoplasia in 27 (Group 2, LSIL), and severe cervical intraepithelial neoplasia in 28 (Group 3, HSIL). A comparative analysis of clinical data and medical history, data of liquid cytology and HPV typing was performed in all patients. Statistical analysis was performed using the MedCalc software package.

RESULTS: The analysis showed that the risk of severe cervical intraepithelial neoplasia increased 5.4-fold in patients aged >30 years, 3.4-fold in smokers, 9.9-fold in patients who had been sexually active for more than 10 years, 6.3-fold in patients who had ≥4 sexual partners, 4.1-fold in patients who used withdrawal method of contraception (coitus interruptus), 7.0-fold in patients who had ≥3 pregnancies, 4.7-fold in patients with HPV infection (in particular, 4.3-fold in women infected with HPV 16). Patients with cervical intraepithelial neoplasia had significantly greater probability to be infected with high-risk HPV types (88.9% in patients with LSIL and 85.7% in patients with HSIL vs. 56.1% in NILM women), in particular, HPV 16 was detected in more than half of patients with HSIL.

CONCLUSION: In this study sample, the risk of cervical intraepithelial neoplasia was associated with age over 30 years, smoking, duration of the sexual activity >10 years, number of sexual partners (>4), lack of barrier contraception, number of past pregnancies (>3), and persisting high-risk HPV infection, especially HPV 16.

Full Text

Restricted Access

About the authors

Maria A. Anisimova

Lomonosov Moscow State University

Author for correspondence.
Email: manecha35@mail.ru
ORCID iD: 0009-0002-6081-5597
SPIN-code: 9561-8400

Graduate Student

Russian Federation, Moscow

Liya N. Shcherbakova

Lomonosov Moscow State University

Email: liya.fbm@gmail.com
ORCID iD: 0000-0003-2681-4777
SPIN-code: 3138-4565

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Andrey E. Bugerenko

Lomonosov Moscow State University

Email: jeddit@yandex.ru
ORCID iD: 0000-0001-5691-7588
SPIN-code: 5827-0440

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, Moscow

Mark Jain

Lomonosov Moscow State University

Email: jain-mark@outlook.com
ORCID iD: 0000-0002-6594-8113
SPIN-code: 3783-4441

Senior Research Associate

Russian Federation, Moscow

Karina I. Kirillova

Lomonosov Moscow State University

Email: dkkirillova@gmail.com
ORCID iD: 0000-0002-0873-7387
SPIN-code: 4440-1859

Research Associate

Russian Federation, Moscow

Larisa M. Samokhodskaya

Lomonosov Moscow State University

Email: slm@fbm.msu.ru
ORCID iD: 0000-0001-6734-3989
SPIN-code: 5404-6202

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Olga B. Panina

Lomonosov Moscow State University

Email: olgapanina@yandex.ru
ORCID iD: 0000-0003-1397-6208
SPIN-code: 2105-6871

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023;11(2):e197–e206. doi: 10.1016/S2214-109X(22)00501-0
  2. Kaczmarek M, Baj-Krzyworzeka M, Bogucki Ł, Dutsch-Wicherek M. HPV-related cervical cancer and extracellular vesicles. Diagnostics. 2022;12(11):2584. doi: 10.3390/diagnostics12112584
  3. Ershov VA. Concepts of the genesis of HPV-associated cervical cancer. Russian News of Clinical Cytology. 2021;25(1):20–29. EDN: KTZKMN doi: 10.24412/1562-4943-2021-1-0004
  4. Faizuloev EB, Kaira AN, Uzbekov TR, et al. The prevalence of high- and low-risk human papillomaviruses in the Russian Federation. Molecular Genetics, Microbiology and Virology. 2021;39(4):39–47. EDN: BJPTLV doi: 10.17116/molgen20213904139
  5. Bogani G, Taverna F, Lombardo C, et al. Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology. Int J Gynaecol Obstet. 2017;138(1):62–68. doi: 10.1002/ijgo.12170
  6. Prisyazhnaya TS, Mikhaylyukova VA, Berlev IV, Malek AV. Risk factors modulating the course of low-grade squamous intraepithelial lesions in women of reproductive age. Tumors of the Female Reproductive System. 2021;17(1):45–52. EDN: MLWJSR doi: 0.17650/1994-4098-2021-17-1-45-52
  7. Bowden SJ, Doulgeraki T, Bouras E, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Medicine. 2023;21(1):274. doi: 10.1186/s12916-023-02965-w
  8. Hortlund M, Mol T, Pol FV, et al. Human papillomavirus load and genotype analysis improves the prediction of invasive cervical cancer. Int J Cancer. 2021;149(3):684–691. doi: 10.1002/ijc.33519
  9. Lam JUH, Rebolj M, Dugue PA, et al. Condom use in prevention of human papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21(1):38–50. doi: 10.1177/0969141314522454
  10. Order of the Ministry of Health of the Russian Federation dated 10/20/2020 No. 1130n “On approval of the Procedure for providing medical care in the field of obstetrics and gynecology”. Publication number: 0001202011130037. Date of publication: 11/13/2020. Available from: http://publication.pravo.gov.ru/Document/View/0001202011130037 (In Russ.)
  11. Feng Q, Balasubramanian A, Hawes SE, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst. 2005;97(4):273–282. doi: 10.1093/JNCI/DJI041
  12. Wei L, Griego AM, Chu M, Ozbun MA. Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes. Carcinogenesis. 2014;35(10): 2373–2381. doi: 10.1093/carcin/bgu156
  13. Stumbar SE, Stevens M, Feld Z. Cervical cancer and its precursors: a preventative approach to screening, diagnosis, and management. Prim Care. 2019:46(1):117–134. doi: 10.1016/j.pop.2018.10.011
  14. Anufrieva VG, Lebedenko EY, Gaida OV, et al. Manageable risk factors for progression of HPV-associated cervical intraepithelial neoplasia. Medical Herald of the South of Russia. 2022;13(2):34–43. EDN: FHPXMW doi: 10.21886/2219-8075-2022-13-2-34-43
  15. Loopik DL, IntHout J, Melchers WJG, et al. Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study. Eur J Cancer. 2020;124:102–109. doi: 10.1016/j.ejca.2019.10.009
  16. Levakov SA, Sheshukova NA, Dabagyan LS. Prevalence and risk factors of cervical intra-epithelial neoplasia. Gynecology, Obstetrics and Perinatology. 2017;16(5):94-100. EDN: ZUKEVJ doi: 10.20953/1726-1678-2017-5-94-100
  17. Pimple S, Mishra G. Cancer cervix: epidemiology and disease burden. Cytojournal. 2022;19:21. doi: 10.25259/CMAS_03_02_2021

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ПИ № ФС 77 - 86335 от 11.12.2023 г.  
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ЭЛ № ФС 77 - 80633 от 15.03.2021 г.